Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 6/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.43 |
| ▸ | MDK | P21741 | 3/20 | 0.42 |
| ▸ | BDNF | P23560 | 3/20 | 0.42 |
| ▸ | PTN | P21246 | 2/20 | 0.42 |
| ▸ | CD69 | Q07108 | 1/20 | 0.40 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.40 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.40 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18608226 | 1.00 | LGALS3 (0.43) | LGALS3LGALS8MAPK1LGALS4MDK | |
| SCHEMBL18608138 | 1.00 | LGALS3 (0.43) | LGALS3LGALS8MAPK1LGALS4MDK | |
| SCHEMBL19325099 | 0.91 | LGALS3 (0.43) | LGALS3LGALS8MAPK1LGALS4MDK | |
| SCHEMBL18936352 | 0.91 | LGALS3 (0.43) | LGALS3LGALS8MAPK1LGALS4MDK | |
| SCHEMBL22137175 | 0.91 | LGALS3 (0.42) | LGALS3LGALS8MAPK1LGALS4MDK | |
| SCHEMBL20021737 | 0.90 | LGALS3 (0.47) | LGALS3LGALS8MAPK1LGALS4MDK | |
| SCHEMBL19818421 | 0.90 | BDNF (0.42) | LGALS3LGALS8MAPK1LGALS4MDK | |
| Dermatan SCHEMBL12691925 | 0.88 | LGALS3 (0.49) | LGALS3LGALS8MAPK1LGALS4MDK | |
| Dermatan SCHEMBL13472480 | 0.88 | LGALS3 (0.49) | LGALS3LGALS8MAPK1LGALS4MDK | |
| Dermatan SCHEMBL19846466 | 0.88 | LGALS3 (0.49) | LGALS3LGALS8MAPK1LGALS4MDK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256109-A1 | Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy | TAMBO, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20220259254-A1 | TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY | TAMBO, INC. | 2022-08-18 | — | — | US | disclosed |
| US-20220168426-A1 | BIOORTHOGONAL COMPOSITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-02 | — | — | US | disclosed |
| US-11253600-B2 | Bioorthogonal compositions | TAMBO, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210128733-A1 | BIOORTHOGONAL COMPOSITIONS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259254-A1 | TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY | TIE1, CD74, MERTK | LGALS3 350/4885LGALS8 93/4885MAPK1 3472/4885 |
| US-20230256109-A1 | Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy | ICOS, CD74, PBK | LGALS3 160/4885LGALS8 29/4885MAPK1 3636/4885 |
| US-20210128733-A1 | BIOORTHOGONAL COMPOSITIONS | TIE1, BBOX1, ST14 | LGALS3 466/4885LGALS8 171/4885MAPK1 3598/4885 |
| US-20220168426-A1 | BIOORTHOGONAL COMPOSITIONS | TIE1, BBOX1, ST14 | LGALS3 466/4885LGALS8 171/4885MAPK1 3598/4885 |
| US-11253600-B2 | Bioorthogonal compositions | TIE1, BBOX1, ST14 | LGALS3 466/4885LGALS8 171/4885MAPK1 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.